Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Figs Inc (FIGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Figs Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $281.66 (market cap $39.89B), while Figs Inc trades at $10.14 (market cap $1.68B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 23.7× Figs Inc's market cap, and Figs Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | FIGS | |
|---|---|---|
Market Cap | $39.89B | $1.68B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $17.12 |
52-Week Low | $278.09 | $5.81 |
Enterprise Value | $38.15B | $1.46B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
FIGS trades at $10.04, down 2.81% today, with a bearish technical signal from moving averages despite recent earnings beats. Revenue grew to $631.10M in 2025 with a 66.61% gross margin, but net cash flow remains negative. Analyst consensus is Buy with a $18.00 price target, suggesting significant upside from current levels.
The stock offers growth potential through healthcare apparel demand and global expansion, but faces risks from valuation multiples (P/E 45.64), margin pressures, and persistent negative cash flow. Investor sentiment is mixed amid cost headwinds and competitive dynamics in the apparel sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →
